Dr. Stiernholm became our President and Chief Executive Officer on our merger with the private company Trillium Therapeutics in April 2013. He joined Trillium from YM BioSciences where he was Executive Vice President and Chief Scientific Officer. While there, he played a significant role in the success of their Initial Public Offering (IPO) in 2002. Dr. Stiernholm began his industry career as a member of Allelix Biopharmaceuticals’ business development office. He currently serves on the board of Vasomune Therapeutics. He received his Ph.D. in immunology from the University of Toronto, where he also completed his postdoctoral training.